Bruce Cohen

Xeraya Capital

Mr. Cohen is a Venture Partner with Xeraya Capital. Prior to joining Xeraya, Mr. Cohen was the founding President and CEO Acacia Biosciences (acquired by Rosetta Inpharmatics), Cellerant Therapeutics and VitaPath Genetics. He previously served as CFO at GeneSoft Pharmaceuticals and held senior positions at SEQUUS Pharmaceuticals and Baxter. He holds a BA and an MA from Tufts University, and an MBA with distinction from Harvard Business School.

Kirk Dornbush

Senior Advisor and Co-Founder

Mr. Dornbush co-founded and served as Iconic’s Chief Executive Officer from 2007 until 2014. Prior to Iconic’s inception in 2003, Mr. Dornbush was President of Diem Investments, a private investment advisory firm. He continues to serve as Manager of Diem Bioventures, LLC, an investor in Iconic. Mr. Dornbush has served on numerous for profit and non-profit Boards including the Board of Directors of the National Park Foundation where he chaired the Foundation’s Investment Committee. Mr. Dornbush received a B.A. in English from The Colorado College and a J.D. from Boston University School of Law.

Todd Foley

MPM Capital

Mr. Foley has served as a member of Iconic Therapeutics’ Board of Directors since April 2014. He is a Managing Director with MPM Capital, a venture capital firm. Prior to joining MPM Capital in 1999, Mr. Foley worked in business development at Genentech and in management consulting with Arthur D. Little. He currently serves as a member of the Board of Directors of Rhythm, Chiasma, OSS, Selexys Pharmaceuticals and Valeritas. Mr. Foley received a B.S. in chemistry from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.

William L. Greene, MD

Chief Executive Officer

Dr. Greene has been Iconic Therapeutics’ CEO and a Director since 2014, bringing 20 years as an operating executive, clinician, investor, and entrepreneur. He joined from MPM Capital, where he was Managing Director and an Investment Committee member, leading investments and serving on Boards of emerging biopharmaceutical and medical device companies.

Previously, Dr. Greene was a Senior Clinical Scientist and Epidemiologist at Genentech, responsible for clinical strategy, trial design and execution, and regulatory interactions in several therapeutic areas at all development stages, including leading the early clinical development of Lucentis®. Before that, he was a Resident in Internal Medicine and Diagnostic Radiology at Yale, and an Assistant Professor of Medicine at UCSF.

Dr. Greene received his B.A. from Wesleyan University and an M.D. from UCSF. He was a Robert Wood Johnson Clinical Scholar at Yale (clinical epidemiology) and a Howard Hughes Medical Institute Research Scholar at the NIH (neurobiology). He is co-founder of and Senior Advisor to Pear Therapeutics, served on the Board of Maverick Therapeutics until its sale to Takeda, and has been a long-standing advisor to the Bill and Melinda Gates Foundation, Worldmedicalguide. He is the founding Chairman of the Board and head of the Investment Committee of the Global Health Investment Fund, the largest impact-oriented life science venture capital fund devoted to global health.

Julia P. Gregory

Ms. Gregory has served as a member of Iconic Therapeutics’ Board of Directors since April 2017. She is a seasoned biotechnology executive with CEO, CFO, board and investment banking skills. She has a proven track record of successfully growing, capitalizing and repositioning private and public biotechnology companies. She is well-versed in corporate governance and SEC issues. She has extensive experience in recruiting outstanding management teams and overcoming significant challenges. As a biotechnology executive, she has raised more than $1.5 billion for biotechnology companies across all types of business cycles and structured creative strategic alliances and transactions for them with pharmaceutical companies including GlaxoSmithKline, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company, Ltd., Genentech, Inc. (now Roche) and Human Genome Sciences (now GSK). Most recently, she was CEO and Board member of ContraFect, which focused on new biologics as an alternative to antibiotics. Prior to ContraFect, she was CEO and Board member of FivePrime Therapeutics, where she led a clinical-stage, biotechnology company discovering and developing innovative protein and antibody therapeutics in the fields of oncology and immunology. She was EVP Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. Prior to her corporate experience, Ms. Gregory was an investment banker for over 20 years primarily as Head of Healthcare and Investment Banking at Punk, Ziegel & Company and at Dillon, Read & Co, Inc. She received a B.A. in international affairs from George Washington University’s Elliott School of International Affairs where she was elected to Phi Beta Kappa and an M.B.A. from The Wharton School of The University of Pennsylvania.

K. Peter Hirth, PhD

Dr. Hirth has served as a member of Iconic Therapeutics’ Board of Directors since May 2015. He has more than 30 years of drug discovery and development expertise. He currently serves as a Board member of Spinomix, KineMed, Kolltan Pharmaceuticals, Afferent Pharmaceuticals and Alios Biopharma. Most recently, Dr. Hirth served as co-founder and CEO of Plexxikon, Inc., where he built a novel, structure-guided drug discovery platform, which has brought several new chemical entities (NCEs) into the clinic such as Zelboraf®, which was approved by the FDA for metastatic melanoma together with a companion diagnostic. Before that, Dr. Hirth was with Sugen Inc., where he was instrumental in building the company from its inception, advancing several kinase inhibitors through clinical trials in oncology. Prior to Sugen, Dr. Hirth was a Vice President of Research at Boehringer Mannheim where he successfully led the company’s erythropoietin program to approval. Earlier in his career, Dr. Hirth was a research scientist with the Max Planck Institute, following the completion of his post-doctoral work at the University of California, San Diego. He received his Ph.D. in molecular genetics from Heidelberg University, Germany.

Bruce Robertson, PhD

H.I.G. BioVentures

Dr. Robertson has served as a member of Iconic Therapeutics’ Board of Directors since April 2014. He is a Managing Director at H.I.G. BioVentures, where he focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices and diagnostics. He currently serves on the Boards of Apollo Endosurgery, CardioFocus, Cerephex, Clarus Therapeutics and Intersection Medical. Prior to joining H.I.G., Dr. Robertson served as Managing Director at Toucan Capital, an early-stage venture capital fund focusing on life science investments, and previously was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the U.S., India, and China. Prior to his venture capital career, Dr. Robertson was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN’s partnering and M&A strategies. He started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices. Dr. Robertson is on the Boards of the Mid-Atlantic Venture Association, Adventist Healthcare, the University of Delaware Research Foundation, and the BioLife Fund of Virginia’s Center for Innovative Technology. He holds a B.S.E. in chemical engineering and a B.A. in mathematics from the University of Pennsylvania, a Ph.D. in chemical/biomedical engineering from the University of Delaware, and an M.B.A. with High Distinction from Harvard Business School.

Dirk Sauer

Independent expert ophthalmology development

Dr. Sauer has more than 31 years of extensive experience in Pharmaceutical Research and Development and successfully led numerous projects and teams during all phases of the drug development process. Dr. Sauer Dirk Novartis in 1989 as a postdoctoral fellow in the Neuroscience Preclinical Research Department. He subsequently held various positions of increasing responsibilities within preclinical research, clinical research and project management working on acute and chronic neurodegenerative diseases such as Stroke, Head Trauma, Parkinson’s Disease, Alzheimer’s Disease and ALS. In 2005 Dr. Sauer  joined the Ophthalmology Business Unit at Novartis as Senior Global Project Leader for Visudyne and Lucentis. In October 2011, he was appointed Global Development Unit Head for the Novartis Ophthalmology Development Unit. Dr. Sauer retired from Novartis in 2021 and is currently an independent consultant and board member for companies within the field of Ophthalmology. He has a degree in Pharmacy from the University of Münster, Germany and a Ph.D. in Pharmacology from the University of Marburg, Germany.